
Cyclosporine: A strong oral immune-suppressing drug used in short bursts for severe eczema and psoriasis. It works faster than anything else, and blood pressure and kidney function set a hard limit on how long anyone stays on it. Humira: An injected biologic for moderate to severe plaque psoriasis. It blocks TNF, one of the main inflammation signals behind psoriasis, and is usually given as a shot under the skin every other week.


Choose for a fast, short burst of control in severe eczema or psoriasis while a longer-term treatment is set up.
Choose for moderate to severe psoriasis or hidradenitis suppurativa — the first approved biologic for HS, now with cheaper biosimilars.
Can you take them together?
Both suppress the immune system, so they are not normally taken together. Cyclosporine is a short-term rescue; Humira is a long-term option.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.











Inhibits calcineurin: Binds cyclophilin to block a T-cell activation switch. Reduces IL-2 signals: Limits a messenger that helps T cells become active. Calms skin inflammation: Overactive immune responses in skin decrease.
Cyclosporine binds cyclophilin; that complex inhibits calcineurin and T-cell cytokine production. This is a simplified skin-focused explanation of systemic immunosuppression.

Binds TNF: Captures an immune messenger that promotes inflammation. Reduces inflammatory signaling: TNF has less ability to activate its receptors. Lets inflamed skin settle: Conditions such as psoriasis can improve over time.
Adalimumab binds TNF-alpha and inhibits its interaction with p55/p75 TNF receptors. This image focuses on skin inflammation; Humira also has other indications.
The dose is set by body weight, then adjusted by blood pressure and kidney tests, not by how the skin looks.
Starting dose: About 2.5 mg per kilogram of body weight a day, split into two doses. A severe flare may start around 4 to 5 mg per kilogram a day to get control quickly.
Going up: Raised in small steps every two to four weeks if response is poor, and only if the tests are stable.
Coming down: Once the skin is calm, the dose comes down in stages, to give the next treatment time to work.
Total course: Short by design. Many courses run 8 to 16 weeks. Guidelines advise no more than about a year of continuous treatment, less where possible.
Adults are not dosed by body weight. You start with a larger loading dose to get levels up fast, then settle into an every-other-week rhythm.
Starting dose: 80 mg on day one, as one 80 mg injection or two 40 mg injections at different spots.
One week later: 40 mg.
Usual dose: 40 mg every other week, the same day of the week each time.
If it stops working: Some people move to weekly injections, others switch drugs. The prescriber's call.
Other conditions: Hidradenitis suppurativa uses a heavier loading dose and weekly maintenance, so do not assume a friend's schedule matches yours.
How long: Long term, with no set course length. It continues while it works and is tolerated.
Twice a day, about 12 hours apart, at the same times daily. Be consistent about food: always with meals or always without, because switching changes absorption. Swallow capsules whole and leave them in the foil until you take them.
On the liquid, mix it with orange or apple juice in a glass cup, stir and drink it straight away, then rinse the cup with more juice and drink that too. Never use grapefruit juice.
Any time of day, but pick a set day of the week and keep to it. Every other week is easy to lose track of, so set a phone reminder on day one.
Take the pen or syringe out of the fridge 15 to 30 minutes before injecting. Cold liquid stings more. Do not warm it in the microwave or hot water.
Inject into the front of the thigh or the belly, at least two inches from the navel. Rotate the spot each time, and avoid skin that is bruised, red, hard, tender or scarred. Never inject through a plaque. A nurse or pharmacist should train you in person for the first dose. Used pens go in a sharps container, never the household bin.
Take it when you remember unless the next dose is close, then skip it. Never take two at once. Tell the prescriber if you miss more than a dose or two, or vomit soon after taking it, because the dose is built around your blood level.
Inject as soon as you remember, then return to your original schedule rather than shifting future doses. Never inject two doses to catch up. If you have missed more than one dose, call the prescriber before restarting — long gaps can blunt how well it works.
Cyclosporine is monitored more closely than any other skin drug, and that monitoring is why it can be used at all. Blood pressure is measured at every visit, often at home. Kidney function is checked by blood test, twice before starting for a reliable baseline, then every couple of weeks for a month or two, then monthly once the dose is steady. The same draws cover potassium, magnesium, uric acid, liver enzymes, blood counts and cholesterol. Drug blood levels are routine in transplant care, not usually needed at dermatology doses.
Two numbers drive the decisions. A rise in creatinine of about a quarter above your baseline, confirmed on a repeat test, means dropping the dose; about half means stopping. New high blood pressure means lowering the dose or adding a blood pressure medicine, and the choice matters: diltiazem and verapamil push levels up, amlodipine does not.
The interaction list is long. Drugs that raise levels include the azole antifungals, clarithromycin and erythromycin, and some HIV and hepatitis C medicines. Drugs that lower it include rifampin, phenytoin, carbamazepine and St John's wort. It also raises statin levels, so that dose is often reduced, and it interacts with colchicine, digoxin, methotrexate and potassium-sparing water tablets. Bring every prescription, supplement and herbal product to the first visit.
The time limit is the point of all this. Kidney damage builds with continuous use and part of it can be permanent, so guidelines cap continuous treatment at about a year and most dermatology courses are far shorter. Long or repeated use also raises the risk of skin cancer, lymphoma and serious infection, so skin checks continue afterward.
Everyone is screened for tuberculosis before the first dose — a skin test or TB blood test, often with a chest X-ray. TNF blockers can wake a dormant TB infection, so a positive screen is treated first and adalimumab waits until that treatment is under way. Testing is often repeated yearly, or sooner if you live somewhere TB is common.
Hepatitis B and C are checked too, because hepatitis B can reactivate when the immune signal is blocked.
After that there is no fixed blood test schedule like methotrexate's. Many doctors check a blood count and liver tests occasionally. Most monitoring is clinical — how the skin looks, and whether you are getting more infections than usual.
Skin should be checked periodically, because TNF blockers are linked to a small increase in skin cancer. The label also carries a boxed warning about serious infections and about lymphoma and other cancers, based mostly on rare cases in children and young adults. The absolute risk is low, but it is why this prescription gets regular review.
Approximate windows, not promises.
First 2 weeksStarting: Itch settles first, often within days, and sleep improves. Tingling or burning in the hands and feet, headache and mild nausea are common early. Blood pressure and kidney tests get checked.
Weeks 2 to 6Working: Redness, weeping and thickness improve clearly. Chronic hives that antihistamines do not control usually settle within a month. Extra hair growth on the face, arms and body and swollen or tender gums start now; both are dose-related and reverse after stopping.
Weeks 8 to 16Plaque psoriasis: Large improvement, often near-clear at the higher end of the dose range. Usually where the course ends and another treatment takes over.
VariableSevere inflammatory ulcers: In pyoderma gangrenosum it stops the ulcer spreading while healing catches up. Response times differ a lot.
ThroughoutThe tests: Blood pressure creeping up and kidney numbers drifting decide whether the dose drops or the drug stops. Neither causes symptoms, which is why the tests are not optional.
First few minutesThe injection: A sting for a few seconds. Injection site reactions, if they happen, show up in the first weeks.
Weeks 1 to 4Starting: Itching often eases before the plaques look different, and some people see the scale thin early.
Weeks 4 to 12Working: Plaques flatten, scale lifts and redness fades from the middle outward. Most of the visible change happens here. Psoriatic arthritis improves on a similar timeline, and hidradenitis suppurativa settles to fewer painful lumps on its own heavier schedule.
Week 16Judge it here: The point the trials measured. Most people reached at least a 75 percent improvement in skin involvement and severity, and a smaller share cleared almost completely.
Months 6 to 12Nails: The slowest, because a nail takes months to grow out. Pitting and lifting improve well after the skin has settled.
After the first yearLong term: Most people who respond keep responding.
Sorted by what to do about them.
Generic capsules are cheap next to biologics, part of why the drug is still used. Branded versions cost more without working better.
The visible cost is not the whole cost. Repeated blood tests, blood pressure checks and appointments add up, and none are optional. It is cheaper per month than a biologic but taken for only a few months, so the comparison depends on what comes after.
Insurance generally covers it for severe psoriasis. Eczema coverage varies more in the United States, where that use is off-label.
The list price is very high, tens of thousands of dollars a year. Almost nobody pays that. What you pay depends on your insurance, and getting there takes paperwork.
Prior authorization is close to universal. Most plans require you to have tried and failed something cheaper first — phototherapy, methotrexate or another systemic drug — and they want records to prove it.
Biosimilars changed the picture. Several have been sold in the United States since 2023, some at much lower list prices. Which one you get is usually decided by your plan's formulary, not your dermatologist, and plans switch year to year. A switch is a paperwork event, not a medical downgrade, though you may need retraining on a different pen.
Manufacturer copay cards can bring the cost down to very little with commercial insurance. By law they cannot be used with Medicare or Medicaid. For those plans, or with no insurance, manufacturer and foundation assistance programs are the usual route, and their rules change often.
Faster than anything else for these conditions. Itch improves within days, clearing by four to six weeks.
Most courses run months. Guidelines cap continuous use at about one year, because kidney effects build and some can be permanent.
It raises blood pressure in a meaningful share of people, and that causes no symptoms. Catching it early usually means lowering the dose rather than stopping.
No. Grapefruit, pomelo and Seville oranges block the enzyme that clears it, so levels rise unpredictably. Other citrus is fine.
Both are dose-related. Not dangerous, usually better if the dose comes down, and gone after stopping.
Usually, within weeks to a few months, unless another treatment is running. Planning that before the taper is the point of the short course.
A large protein grown in living cells rather than a factory chemical. That is why it is injected, and why it lives in the fridge.
A sharp sting for a few seconds. Letting it warm to room temperature first makes a real difference, and citrate-free versions sting less than the original.
Some change by 4 weeks, and about 16 weeks before you judge it fairly. If nothing has happened by then, talk about switching.
Yes, apart from live ones. The flu shot, COVID, pneumonia vaccines and Shingrix are fine and usually recommended. Have live vaccines before you start.
A simple cold is usually not a reason to skip a dose. Anything with a fever, or needing antibiotics, should be checked with the prescriber first.
It must be shown to have no clinically meaningful difference from the original. The pen changes; what is inside does the same job.